

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/012236-2025>

Contract

Rituximab Subcut

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

F20: Modification notice

Notice identifier: 2025/S 000-012236

Procurement identifier (OCID): ocds-h6vhtk-046c75

Published 1 April 2025, 1:00pm

Section I: Contracting authority/entity

I.1) Name and addresses

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

Gyle Square (NSS Head Office), 1 South Gyle Crescent

Edinburgh

EH12 9EB

Email

michelle.semple3@nhs.scot

Telephone

+44 1698794410

Country

United Kingdom

NUTS code

UKM - Scotland

Internet address(es)

Main address

<http://www.nss.nhs.scot/browse/procurement-and-logistics>

Buyer's address

https://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA11883

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Rituximab Subcut

Reference number

NP93420

II.1.2) Main CPV code

- 33600000 - Pharmaceutical products

II.1.3) Type of contract

Supplies

II.2) Description

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products

II.2.3) Place of performance

NUTS codes

- UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement at the time of conclusion of the contract:

The Framework Agreement is for the supply of Rituximab (MabThera®) subcutaneous 1400mg/11.7ml vials to NHS Scotland. The Framework Agreement has been awarded as a single supplier framework agreement to one (1) Framework Participant.

II.2.7) Duration of the contract, framework agreement, dynamic purchasing system or concession

Start date

1 April 2021

End date

31 March 2025

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure
IV.2) Administrative information**IV.2.1) Contract award notice concerning this contract**

Notice number: [2024/S 000-016918](#)

Section V. Award of contract/concession

Contract No

NP93420

Title

Rituximab Subcut

V.2) Award of contract/concession

V.2.1) Date of conclusion of the contract/concession award decision:

28 May 2020

V.2.2) Information about tenders

The contract/concession has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor/concessionaire

Roche Products Ltd

6 Falcon Way, Shire Park

Welwyn Garden City

AL7 1TW

Telephone

+44 1707366171

Country

United Kingdom

NUTS code

- UK - United Kingdom

The contractor/concessionaire is an SME

No

V.2.4) Information on value of the contract/lot/concession (at the time of conclusion of the contract;excluding VAT)

Total value of the procurement: £11,419,194.75

Section VI. Complementary information

VI.3) Additional information

The estimated value(s) of the Framework Agreement referred to in Section V.2.4 covers the twenty-four (24) month contract duration and the thirty-three (33) month extension period of the Framework Agreement.

(SC Ref:789206)

VI.4) Procedures for review

VI.4.1) Review body

Sheriff Court House

27 Chambers Street

Edinburgh

EH1 1LB

Email

edinburgh@scotcourts.gov.uk

Telephone

+44 1312252525

Country

United Kingdom

VI.4.3) Review procedure

Precise information on deadline(s) for review procedures

Economic operators should approach the contracting authority in the first instance. However, the only formal remedy is to apply to the courts:

An economic operator that suffers, or is at risk of suffering, loss, or damage attributable to a breach of duty under the Public Contracts (Scotland) Regulations 2015 or the Procurement Reform (Scotland) Act 2014, may bring proceedings in the Sheriff Court or the Court of Session.

The bringing of court proceedings against the Authority after the Framework Agreement has been entered into will not affect the Framework Agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the Framework Agreement has been entered into are limited to the award of damages.

Section VII: Modifications to the contract/concession

VII.1) Description of the procurement after the modifications

VII.1.1) Main CPV code

- 33600000 - Pharmaceutical products

VII.1.3) Place of performance

NUTS code

- UKM - Scotland

Main site or place of performance

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

VII.1.4) Description of the procurement:

This contract modification, effecting an extension of the Framework Agreement duration from 1 April 2025 until 31 March 2026, has been agreed between the supplier and the

Authority on behalf of NHS Scotland to meet the additional demands of the Scottish Health and Social Care sector.

This modification has been approved to maintain necessary supply due to circumstances unforeseen by the Authority in line with Regulation 72(1)(c) of the Public Contracts (Scotland) Regulations 2015.

VII.1.5) Duration of the contract, framework agreement, dynamic purchasing system or concession

Duration in months

12

VII.1.6) Information on value of the contract/lot/concession (excluding VAT)

Total value of the contract/lot/concession:

£2,404,041

VII.1.7) Name and address of the contractor/concessionaire

Roche Products Ltd

6 Falcon Way, Shire Park

Welwyn Garden City

AL7 1TW

Telephone

+44 1707366171

Country

United Kingdom

NUTS code

- UK - United Kingdom

The contractor/concessionaire is an SME

No

VII.2) Information about modifications

VII.2.1) Description of the modifications

Nature and extent of the modifications (with indication of possible earlier changes to the contract):

This modification effects an extension of the Framework Agreement duration from 1 April 2025 until 31 March 2026. The modification notice is advised at Framework Agreement level only and so it does not detail individual Lots. All Terms and Conditions for the Framework Agreement remain in place.

VII.2.2) Reasons for modification

Need for modification brought about by circumstances which a diligent contracting authority/entity could not foresee.

Description of the circumstances which rendered the modification necessary and explanation of the unforeseen nature of these circumstances:

This modification is necessary to meet the additional demands of the Scottish Health and Social Care sector to maintain necessary supply due to circumstances unforeseen by the Authority, and at this time have rendered this modification necessary, in line with Regulation 72(1)(c) of the Public Contracts (Scotland) Regulations 2015.

VII.2.3) Increase in price

Updated total contract value before the modifications (taking into account possible earlier contract modifications, price adaptations and average inflation)

Value excluding VAT: £11,419,194.75

Total contract value after the modifications

Value excluding VAT: £13,823,235.75